As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a study titled: Durvalumab after chemoradiation in stage III non-small-cell lung cancer: Updated survival outcomes from the PACIFIC trial.
Independent expert commentary is provided by Dr Melissa Moore, a medical oncologist with sub-specialty interests in cancers of the lung, breast, and upper gastrointestinal tract.
Please login below to download this issue (PDF)